This is the first study demonstrating coordinated overexpression of CD74 and CTSL and proposing their dual targeting via antibody-drug conjugates (ADCs) to improve outcomes in relapsed or refractory DLBCL. The gene discussed is CTSL; the disease is diffuse large B-cell lymphoma.